Patients with CR had favorable baseline laboratory characteristics, such as lower total bilirubin (median 0.6 vs. 0.8 mg/dL), higher serum albumin level (median 4.1 vs. 3.9 g/dL), lower model for end-stage liver disease (MELD) score (median 6.0 vs. 7.0), and lower albumin-bilirubin (ALBI) gradient score (median −2.8 vs. −2.5) compared to patients who did not achieve CR (all p < 0.05). This evidence concerns the gene ALB and liver disorder.